The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 743-752

  Nagaprashantha, Lokesh Dalasanur ^a   Vatsyayan, Rit ^a   Lelsani, Poorna Chandra Rao ^a   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

anoikis; cell matrix interactions; drug resistance; metastasis

Indexed keywords

CADHERIN; CAVEOLIN 1; CD147 ANTIGEN; CELL ADHESION MOLECULE; CISPLATIN; FLUOROURACIL; GALECTIN 3; GEMCITABINE; INTEGRIN; PROTEIN SIP 1; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANOIKIS; ARTICLE; CELL CONTACT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INVASION; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR RESISTANCE;

ANIMALS; ANOIKIS; CELL-MATRIX JUNCTIONS; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 78650622904     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25725     Document Type: Article

References (115)

1. Frisch SM, Francis H,. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
2. Liotta LA, and, Kohn E,. Anoikis: cancer and the homeless cell. Nature 2004; 430: 973-4.
3. Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, Yamazaki M, Ngan CY, Yamamoto H, Ma Q,. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology 2008; 75: 17-26.
4. Tanaka K, Mohri Y, Nishioka J, Kobayashi M, Ohi M, Miki C, Tonouchi H, Nobori T, Kusunoki M,. Neurotrophic receptor, tropomyosin-related kinase B as an independent prognostic marker in gastric cancer patients. J Surg Oncol 2009; 99: 307-10.
5. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT,. Rational basis for trk inhibition therapy for prostate cancer. Prostate 2000; 45: 140-8.
6. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM,. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62: 6462-6.
7. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS,. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034-9.
8. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L,. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001; 20: 4942-50.
9. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M,. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203.
10. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X,. Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 2007; 358: 925-30.
11. Tester AM, Ruangpanit N, Anderson RL, Thompson EW,. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 2000; 18: 553-60.
12. Yan W, Shao R,. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 2006; 281: 19700-8.
13. Ahmed N, Abubaker K, Findlay J, Quinn M,. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10: 268-78.
14. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP,. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992; 52: 5190-7.
15. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute, Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Available at:. Retrieved on September 2010.
16. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W,. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-8.
17. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH,. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-7.
18. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA,. Correlation of snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002: 21: 3241-6.
19. Peinado H, Ballestar E, Esteller M, Cano A,. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004; 24: 306-19.
20. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA,. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18; 1131-43.
21. Schlessinger K, Hall A,. GSK-3beta sets snail's pace. Nat Cell Biol 2004; 6: 913-5.
22. Comijn J, Berx G, Vermassen P, Verschueren K, Grunsven VL, Bruyneel E, Mareel M, Huylebroeck D, Roy VF,. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001; 7: 1267-78.
23. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, Miyazaki K,. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 2004; 90: 1265-73.
24. Maeda G, Chiba T, Aoba T, Imai K,. Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology 2007; 95: 24-9.
25. Venkov CD, Link AJ, Jennings JL, Plieth D, Inoue T, Nagai K, Xu C, Dimitrova YN, Rauscher FJ, Neilson EG,. A proximal activator of transcription in epithelial-mesenchymal transition. J Clin Invest 2007; 117: 482-91.
26. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG,. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405.
27. Okada H, Danoff TM, Kalluri R, Neilson EG,. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273: F563-74.
28. Nowak J, Mosor M, Ziolkowska I, Wierzbicka M, Pernak-Schwarz M, Przyborska M, Roznowski K, Plawski A, Slomski R, Januszkiewicz D,. Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. Eur J Cancer 2008; 44: 627-30.
29. Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, Teng SC, Wu KJ,. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and snail predicts metastasis of head and neck cancer. Oncogene 2007; 26: 1459-67.
30. Yan L, Zucker S, Toole BP,. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199-204.
31. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, Pantel K,. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10: 3422-8.
32. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, Lomas M, Arndt GM, Tang Y, Nakada M, Yan L, Hait WN,. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. J Biol Chem 2006; 14 281: 9719-27.
33. Hynes RO,. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
34. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G, Legrand JF, Als-Nielsen J, Colman DR, Hendrickson WA,. Structural basis of cell-cell adhesion by cadherins. Nature 1995; 374: 327-37.
35. Chandrasekaran EV, Jain RK, Larsen RD, Wlasichuk K, Matta KL,. Selectin ligands and tumor-associated carbohydrate structures: specificities of alpha 2,3-sialyltransferases in the assembly of 3′-sialyl-6-sialyl/sulfo lewis a and x, 3′-sialyl-6′-sulfo lewis x, and 3′-sialyl-6-sialyl/ sulfo blood group T-hapten. Biochemistry 1995; 34: 2925-36.
36. Kamiguchi H, and, Lemmon V,. IgCAMs: bidirectional signals underlying neurite growth. Curr Opin Cell Biol 2000; 12: 598-605.
37. Loftus JC, Liddington RC,. Cell adhesion in vascular biology. New insights into integrin-ligand interaction. J Clin Invest 1997; 100: 2302-2306.
38. Humphries MJ, Newham P,. The structure of cell-adhesion molecules. Trends Cell Biol 1998; 8: 78-83.
39. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P,. Integrin-mediated signal transduction linked to ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994; 372: 786-91.
40. Chen Q, Lin TH, Der CJ, Juliano RL,. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of ras. J Biol Chem 1996; 271: 18122-7.
41. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG,. The adaptor protein shc couples a class of integrins to the control of cell cycle progression. Cell 1996; 87: 733-43.
42. Zutter MM,. Integrin-mediated adhesion: tipping the balance between chemo-sensitivity and chemo-resistance. Adv Exp Med Biol 2007; 608: 87-100.
43. Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, Tsuruo T, Beaulieu JF, Gauthier R, Vezina A, Villeneuve L,. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol 2007; 212: 717-28.
44. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ,. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, bim. J Biol Chem 2003; 278: 18811-6.
45. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK, Brugge JS,. Integrins and EGFR coordinately regulate the pro-apoptotic protein bim to prevent anoikis. Nat Cell Biol 2003; 5: 733-40.
46. Samuels Y, Ericson K,. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
47. Watt FM,. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J 2002; 21: 3919-26.
48. Carter WG, Wayner EA, Bouchard TS, Kaur P,. The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 1990; 110: 1387-404.
49. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W,. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995; 108: 2241-51.
50. Haapasalmi K, Zhang K, Tonnesen M, Olerud J, Sheppard D, Salo T, Kramer R, Clark RA, Uitto VJ, Larjava H,. Keratinocytes in human wounds express alpha v beta 6 integrin. J Invest Dermatol 1996; 106: 42-8.
51. Jones J, Watt FM, Speight PM,. Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 1997; 26: 63-8.
52. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC,. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002; 38: 332-6.
53. Janes SM, Watt FM,. Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis. J Cell Biol 2004; 166: 419-31.
54. Montgomery AM, Reisfeld RA, Cheresh DA,. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856-60.
55. Chen H, Choudhury DM, Craig SW,. Coincidence of actin filaments and talin is required to activate vinculin. J Biol Chem 2006; 281: 40389-40398.
56. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, Liu SC, Low PS, Rouleau GA, Mohandas N, Chasis JA, Conboy JG, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 1998; 23: 281-2.
57. Garcia-Alvarez B, de Pereda JM, Calderwood DA, Ulmer TS, Critchley D, Campbell ID, Ginsberg MH, Liddington RC,. Structural determinants of integrin recognition by talin. Mol Cell 2003: 11: 49-58.
58. Gilmore AP, Ohanian V, Spurr NK, Critchley DR,. Localisation of the human gene encoding the cytoskeletal protein talin to chromosome 9p. Hum Genet 1995; 96: 221-4.
59. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP,. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55: 342-7.
60. Genini M, Schwalbe P, Scholl FA, Schafer BW,. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 1996; 66: 571-7.
61. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004; 135: 555-62.
62. Hanks SK, Ryzhova L, Shin NY, Brabek J,. Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 2003; 8: 982-96.
63. Gabarra-Niecko V, Schaller MD, Dunty JM,. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003; 22: 359-74.
64. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH,. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-jun NH(2)-terminal kinase. J Cell Biol 2000; 149: 741-54.
65. Kurenova E, Xu LH, Yang X, Baldwin AS, Jr, Craven RJ, Hanks SK, Liu ZG, Cance WG,. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 2004; 24: 4361-71.
66. Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV,. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med 1996; 23: 145-9.
67. Furukawa K, Hamamura K, Aixinjueluo W, Furukawa K,. Biosignals modulated by tumor-associated carbohydrate antigens: novel targets for cancer therapy. Ann N Y Acad Sci 2006; 1086: 185-98.
68. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N,. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 1987; 84: 2251-5. (Pubitemid 17075849)
69. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W,. Pp60c-src activation in human colon carcinoma. J Clin Invest 1989; 83: 2025-33.
70. Talamonti MS, Roh MS, Curley SA, Gallick GE,. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91: 53-60.
71. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE,. Activation of src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94: 344-51.
72. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE,. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-807.
73. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y,. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001; 276: 31858-62.
74. Glenney JR, Jr, Zokas L,. Novel tyrosine kinase substrates from rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 1989; 108: 2401-8.
75. Birge RB, Fajardo JE, Reichman C, Shoelson SE, Songyang Z, Cantley LC, Hanafusa H,. Identification and characterization of a high-affinity interaction between v-crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Mol Cell Biol 1993; 13: 4648-56.
76. Wei L, Yang Y, Zhang X, Yu Q,. Cleavage of p130Cas in anoikis. J Cell Biochem 2004; 91: 325-35.
77. Wei L, Yang Y, Zhang X, Yu Q,. Anchorage-independent phosphorylation of p130(cas) protects lung adenocarcinoma cells from anoikis. J Cell Biochem 2002; 87: 439-49.
78. Papagrigoriou E, Gingras AR, Barsukov IL, Bate N, Fillingham IJ, Patel B, Frank R, Ziegler WH, Roberts GC, Critchley DR, Emsley J,. Activation of a vinculin-binding site in the talin rod involves rearrangement of a five-helix bundle. EMBO J 2004; 23: 2942-51.
79. Pokutta S, Weis WI,. The cytoplasmic face of cell contact sites. Curr Opin Struct Biol 2002; 12: 255-62.
80. Izard T, Evans G, Borgon RA, Rush CL, Bricogne G, Bois PR,. Vinculin activation by talin through helical bundle conversion. Nature 2004; 427: 171-5.
81. Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM,. Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 2004; 165: 371-81.
82. Parise LV, Lee J, Juliano RL,. New aspects of integrin signaling in cancer. Semin Cancer Biol 2000; 10: 407-14.
83. Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, Rempel SA,. PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro-Oncology 2010; 12: 941-55.
84. Maehama T, Taylor GS, Dixon JE,. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70: 247-79.
85. Dedhar S,. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol 2000; 12: 250-6.
86. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A,. The proapoptotic activity of the bcl-2 family member bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-96.
87. Bazou D, Dowthwaite GP, Khan IM, Archer CW, Ralphs JR,. Coakley WT. Gap junctional intercellular communication and cytoskeletal organization in chondrocytes in suspension in an ultrasound trap. Mol Membr Biol 2006; 23: 195-205.
88. Meloni MA, Galleri G, Pippia P, Cogoli-Greuter M,. Cytoskeleton changes and impaired motility of monocytes at modelled low gravity. Protoplasma 2006: 229: 243-249.
89. Strasser A, Puthalakath H, Bouillet P, Huang DC, O'Connor L, O'Reilly LA, Cullen L, Cory S, Adams JM,. The role of bim, a proapoptotic BH3-only member of the bcl-2 family in cell-death control. Ann N Y Acad Sci 2000; 917: 541-8.
90. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC, Strasser A,. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-32.
91. Takeichi M,. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619-27.
92. Tepass U, Truong K, Godt D, Ikura M, Peifer M,. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol 2000; 1: 91-100.
93. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, Roy VF,. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 24: 6107-15.
94. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S,. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416-9.
95. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-73.
96. Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laronze JY, Bonnet N, Foidart JM, Mareel M, Birembaut P,. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003; 105: 790-5.
97. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10: 437-49.
98. Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH,. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007; 67: 3094-105.
99. Cavallaro U, Christofori G,. Cell adhesion and signalling by cadherins and ig-CAMs in cancer. Nat Rev Cancer 2004; 4: 118-32.
100. Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM, Stanners CP,. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol 2007; 210: 757-65.
101. Camacho-Leal P, Zhai AB, Stanners CP,. A co-clustering model involving alpha5beta1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA). J Cell Physiol 2007; 211: 791-802.
102. Naghibalhossaini F, Yoder AD, Tobi M, Stanners CP,. Evolution of a tumorigenic property conferred by glycophosphatidyl-inositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol Biol Cell 2007; 18: 1366-74.
103. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004; 23: 465-73.
104. Fine SW, Lisanti MP, Galbiati F, Li M,. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 2001; 115: 719-24.
105. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC,. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008: 59: 105-10.
106. Ravid D, Maor S, Werner H, Liscovitch M,. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005; 24: 1338-47.
107. Lee NP, Luk JM,. Hepatic tight junctions: from viral entry to cancer metastasis. World J Gastroenterol 2010; 16: 289-95.
108. Kominsky SL,. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006; 8: 1-11.
109. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T,. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008; 11: 1098-1111.
110. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI., Han HS, Kim JC, Kim MK,. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002; 3: 382-387.
111. Lin HM, Pestell RG, Raz A, Kim HR,. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002; 21: 8001-10.
112. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A,. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002; 277: 6852-7.
113. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, Brugge JS,. G1/S cell cycle arrest provides anoikis resistance through erk-mediated bim suppression. Mol Cell Biol 2005; 25: 5282-91.
114. Lin HM, Moon BK, Yu F, Kim HR,. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000; 11: 1941-1945.
115. Kim HR, Lin HM, Biliran H, Raz A,. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 16: 4148-4154.